F. Di Perna

684 total citations
21 papers, 530 citations indexed

About

F. Di Perna is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, F. Di Perna has authored 21 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 4 papers in Epidemiology. Recurrent topics in F. Di Perna's work include Chronic Obstructive Pulmonary Disease (COPD) Research (15 papers), Asthma and respiratory diseases (13 papers) and Inhalation and Respiratory Drug Delivery (10 papers). F. Di Perna is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (15 papers), Asthma and respiratory diseases (13 papers) and Inhalation and Respiratory Drug Delivery (10 papers). F. Di Perna collaborates with scholars based in Italy, Argentina and Czechia. F. Di Perna's co-authors include Mario Cazzola, Maria Gabriella Matera, Francesco Calderaro, Annamaria Vinciguerra, Antonello Salzillo, Francesco Imperatore, Stefano Centanni, Maria D’Amato, Paolo Noschese and R. Testi and has published in prestigious journals such as SHILAP Revista de lepidopterología, CHEST Journal and European Respiratory Journal.

In The Last Decade

F. Di Perna

21 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Di Perna Italy 14 467 396 39 30 28 21 530
Paolo Noschese Italy 13 188 0.4× 193 0.5× 35 0.9× 14 0.5× 22 0.8× 24 376
E J Hiller United Kingdom 11 298 0.6× 213 0.5× 4 0.1× 61 2.0× 11 0.4× 16 385
John Kottakis United Kingdom 16 644 1.4× 576 1.5× 16 0.4× 7 0.2× 20 0.7× 19 679
DD Sin Canada 5 215 0.5× 141 0.4× 15 0.4× 15 0.5× 5 0.2× 8 294
Ingrid Solanes Spain 11 249 0.5× 112 0.3× 14 0.4× 63 2.1× 28 1.0× 24 369
Nigel D. Dore Australia 7 236 0.5× 160 0.4× 2 0.1× 33 1.1× 14 0.5× 7 292
Adam Nowiński Poland 8 175 0.4× 109 0.3× 9 0.2× 34 1.1× 13 0.5× 32 254
Tomás Posadas Spain 11 263 0.6× 104 0.3× 14 0.4× 94 3.1× 34 1.2× 22 361
Tammy Abuan United States 9 325 0.7× 63 0.2× 30 0.8× 150 5.0× 25 0.9× 9 460
Yewon Kang South Korea 10 145 0.3× 162 0.4× 5 0.1× 18 0.6× 29 1.0× 22 327

Countries citing papers authored by F. Di Perna

Since Specialization
Citations

This map shows the geographic impact of F. Di Perna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Di Perna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Di Perna more than expected).

Fields of papers citing papers by F. Di Perna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Di Perna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Di Perna. The network helps show where F. Di Perna may publish in the future.

Co-authorship network of co-authors of F. Di Perna

This figure shows the co-authorship network connecting the top 25 collaborators of F. Di Perna. A scholar is included among the top collaborators of F. Di Perna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Di Perna. F. Di Perna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scrima, Marianna, Alessia Maria Cossu, Marco Bocchetti, et al.. (2022). Genomic Characterization of the Emerging SARS-CoV-2 Lineage in Two Districts of Campania (Italy) Using Next-Generation Sequencing. SHILAP Revista de lepidopterología. 2. 4 indexed citations
2.
Cossu, Alessia Maria, Marianna Scrima, Vincenzo Messina, et al.. (2021). Efficacy of Unsupervised Self-Collected Mid-Turbinate FLOQSwabs for the Diagnosis of Coronavirus Disease 2019 (COVID-19). Viruses. 13(8). 1663–1663. 5 indexed citations
3.
Cazzola, Mario, F. Di Perna, Maria D’Amato, et al.. (2002). Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Respiratory Medicine. 96(10). 790–795. 17 indexed citations
4.
5.
Cazzola, Mario, et al.. (2002). Long-Acting ??2-Agonists in the Treatment of Acute Exacerbations of COPD. Clinical Drug Investigation. 22(6). 369–376. 8 indexed citations
6.
Cazzola, Mario, Stefano Centanni, Fabiano Di Marco, et al.. (2001). Onset of Action of Single Doses of Formoterol Administered via Turbuhaler in Patients with Stable COPD. Pulmonary Pharmacology & Therapeutics. 14(1). 41–45. 37 indexed citations
7.
Cazzola, Mario, et al.. (2001). Formoterol Turbuhaler®for as-needed therapy in patients with mild acute exacerbations of COPD. Respiratory Medicine. 95(11). 917–921. 24 indexed citations
8.
9.
Cazzola, Mario, Gabriele Di Lorenzo, F. Di Perna, et al.. (2000). Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD. CHEST Journal. 118(6). 1576–1581. 59 indexed citations
10.
Cazzola, Mario, et al.. (1999). Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respiratory Medicine. 93(12). 909–911. 14 indexed citations
11.
12.
Cazzola, Mario, Annamaria Vinciguerra, F. Di Perna, et al.. (1999). Comparative Study of Dirithromycin and Azithromycin in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Journal of Chemotherapy. 11(2). 119–125. 14 indexed citations
13.
Cazzola, Mario, et al.. (1999). Incremental Benefit of Adding Oxitropium Bromide to Formoterol in Patients with Stable COPD. Pulmonary Pharmacology & Therapeutics. 12(4). 267–271. 11 indexed citations
14.
Cazzola, Mario, Francesco Imperatore, Antonello Salzillo, et al.. (1998). Cardiac Effects of Formoterol and Salmeterol in Patients Suffering from COPD with Preexisting Cardiac Arrhythmias and Hypoxemia. CHEST Journal. 114(2). 411–415. 144 indexed citations
15.
Cazzola, Mario, Annamaria Vinciguerra, F. Di Perna, & Maria Gabriella Matera. (1998). Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. Respiratory Medicine. 92(8). 1012–1016. 21 indexed citations
16.
Cazzola, Mario, et al.. (1998). A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respiratory Medicine. 92(2). 354–357. 26 indexed citations
17.
Cazzola, Mario, F. Di Perna, Paolo Noschese, et al.. (1998). Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. European Respiratory Journal. 11(6). 1337–1341. 35 indexed citations
18.
Cazzola, M., et al.. (1998). [Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage].. PubMed. 89(1-2). 15–22. 2 indexed citations
19.
Cazzola, Mario, M Caputi, G Santangelo, et al.. (1997). A Five-Day Course of Dirithromycin in the Treatment of Acute Exacerbation of Severe Chronic Obstructive Pulmonary Disease. Journal of Chemotherapy. 9(4). 279–284. 8 indexed citations
20.
Matera, Maria Gabriella, Mario Cazzola, Annamaria Vinciguerra, et al.. (1995). A comparison of the bronchodilating effects of salmeterol, salbutamol and Ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology. 8(6). 267–271. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Noschese Breakdown of academic impact, for papers by E J Hiller Breakdown of academic impact, for papers by John Kottakis Breakdown of academic impact, for papers by DD Sin Breakdown of academic impact, for papers by Ingrid Solanes Breakdown of academic impact, for papers by Nigel D. Dore Breakdown of academic impact, for papers by Adam Nowiński Breakdown of academic impact, for papers by Tomás Posadas Breakdown of academic impact, for papers by Tammy Abuan Breakdown of academic impact, for papers by Yewon Kang
Rankless by CCL
2026